Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2008

View Archived Issues

Recent Wonkisopharm patent reports novel therapeutic option for skin hyperpigmentation

Novel analgesic agents disclosed in recent patent literature

New therapeutic agents for neurological disorders reported in recent patents

Targeting the PI3K/Akt pathway beneficial against HIV infection

Positive preclinical results with staphylococcal enterotoxin B vaccine (STEBVax)

Acceleron and Celgene enter collaboration for ACE-011 cancer-related bone loss

Avexa initiates first test site for phase III trial of apricitabine for HIV

Sequenom reports encouraging results with noninvasive prenatal test for Down's syndrome

AGI Therapeutics reports key findings from pharmacokinetic study of Rezular

Sirtris enters agreement with the National Cancer Institute to test SIRT1 enzyme activators

Novel 5-HT6 receptor antagonist potentially useful as cognition enhancer

Allon Therapeutics adds Alzheimer's patients to ongoing phase II clinical trial of AL-108

PharmaIN received grant of USD 400,000 from the NIH for PGC-lysostaphin

Adherex receives FDA orphan drug designation for ADH-1 in melanoma

EMEA recommends marketing authorization of Ipsen's Adenuric

FDA grants priority review for prasugrel in acute coronary syndrome

ImClone Systems enrolls first patient in disease-directed phase II IMC-1121B trial

Sosei initiates a phase III trial for NorLevo

New oncolytic virus shows activity against brain and peripheral tumors

GSK receives CHMP positive opinion for Volibris

FDA to accelerate approval of Avastin plus paclitaxel as first-line breast cancer therapy

BioAlliance to acquire Immtech products despite pafuramidine program discontinuation

FDA approves Abbott's Humira for polyarticular juvenile idiopathic arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...